Pharmacy Disclosure Log 2025

1. Atopic Dermatitis Response 981
2. Biologic Medicines in Gastroenterology Response 847
3. Biologics Rheumatology Response 762
4. Blood Cultures Response 940
5. Dermatology and Respiratory Medicine Response 977
6. Dermatology Response 771
7. Diffuse Large B Cell Lymphoma Response 827
8. Endometrial Cancer Response 923
9. Eosinophilic Oesophagitis (EoE) Response 972
10. Fibrinogen Concentrate, Prothrombin Complex Concentrate, DOAC Antidote, and Blood Products Response 772
11. Fibrinogen Concentrate, Prothrombin Complex Concentrate, DOAC Antidote, and blood Products Response 772 Attachment
12. Formularies and Committees Response 941
13. Friedreich Ataxia Response 921
14. Human Albumin Response 826
15. Immunoglobulin Treatment Response 932
16. Intra-Vitreal Injections Implants Response 810
17. Intra-vitreal treatments Response 870
18. Lung Cancer Response 864
19. Lung Cancer Response 864 Attachment
20. Medication errors Rocuronium Response 918
21. Melanoma Response 901
22. Migraine Response 856
23. New Biologic and Targeted Medications Response 867
24. Non-Medical uses of Blood Response 802
25. NHS Pharmacy Aseptic Services Response 803
26. Oncology Breast Cancer Response 857
27. Oncology Response 928
28. Ovarian Cancer Response 944
29. Patients treated with Ruxolitinib Response 933
30. Patients treated with Ruxolitinib Response 933 Attachment
31. Primary Diagnosis of GCA Response 784
32. Renal Cell Carcinoma Response 871
33. Renal Cell Carcinoma Response 871 Attachment
34. Spinal Muscular Atrophy Response 794
35. Trust Processes to Reduce Medication Waste Response 885
36. Urothelial Cancer Response 930
37. Wound Formulary Response 860